To compare oral Sildenafil and Bosentan in the treatment of pulmonary hypertension in neonates
Not Applicable
- Conditions
- Health Condition 1: P293- Persistent fetal circulation
- Registration Number
- CTRI/2022/06/043328
- Lead Sponsor
- Department of Neonatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Neonates with 34 weeks of completed gestational age who are echocardiographically diagnosed to have Persistent pulmonary hypertension of the newborn defined as
1.PASP of more than 35 mm of Hg calculation by TR peak jet velocity and Fio2 requirement > 21%
Exclusion Criteria
1. Congenital heart disease (Except patent ductus arteriosus, atrial septal defect ( <6mm), or a single, small muscular ventricular septal defect ( <4 mm)
2. Congenital diaphragmatic hernia
3. Lethal congenital anomaly
4. Babies with severe PPHN with Oxygenation index (OI) > 15 and directly started on inhaled nitric oxide (iNO) on diagnosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method